Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
Precision Medicine Market Is Expected To Reach Revenue Of USD 225.7 Bn By 2033, At 11.6% CAGR: Dimension Market Research
10 sept. 2024 11h03 HE
|
Dimension Market Research
New York, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Overview The Global Precision Medicine Market is to reach USD 83.9 billion by 2024 and is further anticipated to reach USD 225.7 billion by 2033...
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
06 sept. 2024 06h48 HE
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Turkey Cancer Drugs Clinical Trials Market Research 2024 Featuring OMEGA CRO, mediSMART, CRM-CRO, CROTURK, and Klinar CRO
05 sept. 2024 04h21 HE
|
Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Turkey Cancer Drugs Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. Turkey presents an expanding...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 sept. 2024 16h15 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Down Syndrome Clinical Trials Review, 2024: Key Trends, Leading Companies, Latest Developments - Create Effective Counter Strategies to Gain a Competitive Advantage
04 sept. 2024 10h42 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Down Syndrome - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report offers a...
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
04 sept. 2024 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the...
Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
04 sept. 2024 07h30 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics presents new positive data at SSIEM 2024 from Phase 1/2 study of JNT-517 in individuals with phenylketonuria (PKU).